Copyright
©The Author(s) 2021.
World J Clin Oncol. Mar 24, 2021; 12(3): 164-182
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.164
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.164
Table 1 Historical outcomes in metastatic triple negative breast cancer
ORR (%) | PFS (mo) | OS (mo) | |
Single agent chemotherapy | |||
1L | 10.0-28.0 | 3.5-5.4 | 9.9-17.5 |
2L | 6.0-18.0 | 2.7-3.4 | 9.2-15.2 |
Combination chemotherapy | |||
1L | 14.8-64.3 | 4.8-9.0 | 13.9-24.2 |
2L+ | 27.01-60.0 | 2.9-7.0 | 8.1-16.5 |
- Citation: O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021; 12(3): 164-182
- URL: https://www.wjgnet.com/2218-4333/full/v12/i3/164.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i3.164